Nipaporn Pichetshote, MD
Gastroenterology · Los Angeles, CANPI 1033375910
Payments from drug & device makers
Across 6 payments — averaging $6730.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$31K
- Bausch Health US, LLC$9K
- Vibrant Gastro, Inc.$200
- Boston Scientific$161
- Nestle Healthcare Nutrition Inc.$25
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$18
Across 21 payments — averaging $2040.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$43K
What the payments were for
- Consulting fees$20049%
- Food & beverage$20451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 1 | $31,185 |
| Bausch Health US, LLC | 1 | $8,792 |
| Vibrant Gastro, Inc. | 1 | $200 |
| Boston Scientific | 1 | $161 |
| Nestle Healthcare Nutrition Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,381 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MotegrityPrucalopride Succinate | 25 | $14,849 |
| LinzessLinaclotide | 17 | $11,395 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 40 | $524 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 17 | $267 |
| Omeprazole | 16 | $263 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Los Angeles
- Gil MelmedLos Angeles$3M
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$2M
- Caroline HwangLos Angeles$908K
- Andres YarurLos Angeles$903K
- Brennan SpiegelLos Angeles$845K
- Nicholas KaryotakisLos Angeles$710K
- Venkataraman MuthusamyLos Angeles$693K
- Sadeea AbbasiLos Angeles$556K
- Peter WinkleCypress$116.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.